These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

447 related items for PubMed ID: 26740407

  • 1. Chronic low-dose melatonin treatment maintains nigrostriatal integrity in an intrastriatal rotenone model of Parkinson's disease.
    Carriere CH, Kang NH, Niles LP.
    Brain Res; 2016 Feb 15; 1633():115-125. PubMed ID: 26740407
    [Abstract] [Full Text] [Related]

  • 2. Neuroprotection by valproic acid in an intrastriatal rotenone model of Parkinson's disease.
    Carriere CH, Kang NH, Niles LP.
    Neuroscience; 2014 May 16; 267():114-21. PubMed ID: 24613722
    [Abstract] [Full Text] [Related]

  • 3. Altered melatonin MT1 receptor expression in the ventral midbrain following 6-hydroxydopamine lesions in the rat medial forebrain bundle.
    Kang NH, Carriere CH, Bahna SG, Niles LP.
    Brain Res; 2016 Dec 01; 1652():89-96. PubMed ID: 27693415
    [Abstract] [Full Text] [Related]

  • 4. Bilateral upregulation of α-synuclein expression in the mouse substantia nigra by intracranial rotenone treatment.
    Carriere CH, Kang NH, Niles LP.
    Exp Toxicol Pathol; 2017 Feb 01; 69(2):109-114. PubMed ID: 27986376
    [Abstract] [Full Text] [Related]

  • 5. Melatonin treatment potentiates neurodegeneration in a rat rotenone Parkinson's disease model.
    Tapias V, Cannon JR, Greenamyre JT.
    J Neurosci Res; 2010 Feb 01; 88(2):420-7. PubMed ID: 19681169
    [Abstract] [Full Text] [Related]

  • 6. Acute intranigral infusion of rotenone in rats causes progressive biochemical lesions in the striatum similar to Parkinson's disease.
    Saravanan KS, Sindhu KM, Mohanakumar KP.
    Brain Res; 2005 Jul 12; 1049(2):147-55. PubMed ID: 15936733
    [Abstract] [Full Text] [Related]

  • 7. L-deprenyl protects against rotenone-induced, oxidative stress-mediated dopaminergic neurodegeneration in rats.
    Saravanan KS, Sindhu KM, Senthilkumar KS, Mohanakumar KP.
    Neurochem Int; 2006 Jul 12; 49(1):28-40. PubMed ID: 16490285
    [Abstract] [Full Text] [Related]

  • 8. Quercetin up-regulates mitochondrial complex-I activity to protect against programmed cell death in rotenone model of Parkinson's disease in rats.
    Karuppagounder SS, Madathil SK, Pandey M, Haobam R, Rajamma U, Mohanakumar KP.
    Neuroscience; 2013 Apr 16; 236():136-48. PubMed ID: 23357119
    [Abstract] [Full Text] [Related]

  • 9. Rats with unilateral median forebrain bundle, but not striatal or nigral, lesions by the neurotoxins MPP+ or rotenone display differential sensitivity to amphetamine and apomorphine.
    Sindhu KM, Banerjee R, Senthilkumar KS, Saravanan KS, Raju BC, Rao JM, Mohanakumar KP.
    Pharmacol Biochem Behav; 2006 Jun 16; 84(2):321-9. PubMed ID: 16820197
    [Abstract] [Full Text] [Related]

  • 10. Sodium salicylate protects against rotenone-induced parkinsonism in rats.
    Madathil SK, Karuppagounder SS, Mohanakumar KP.
    Synapse; 2013 Aug 16; 67(8):502-14. PubMed ID: 23447126
    [Abstract] [Full Text] [Related]

  • 11. Neuroprotective and antidepressant-like effects of melatonin in a rotenone-induced Parkinson's disease model in rats.
    Bassani TB, Gradowski RW, Zaminelli T, Barbiero JK, Santiago RM, Boschen SL, da Cunha C, Lima MM, Andreatini R, Vital MA.
    Brain Res; 2014 Dec 17; 1593():95-105. PubMed ID: 25301688
    [Abstract] [Full Text] [Related]

  • 12. Effects of Aging in the Striatum and Substantia Nigra of a Parkinson's Disease Animal Model.
    Ureshino RP, Costa AJ, Erustes AG, Pereira GJDS, Sinigaglia-Coimbra R, Smaili SS.
    Toxicol Pathol; 2018 Apr 17; 46(3):348-358. PubMed ID: 29683090
    [Abstract] [Full Text] [Related]

  • 13. Characterisation of a novel model of Parkinson's disease by intra-striatal infusion of the pesticide rotenone.
    Mulcahy P, Walsh S, Paucard A, Rea K, Dowd E.
    Neuroscience; 2011 May 05; 181():234-42. PubMed ID: 21277943
    [Abstract] [Full Text] [Related]

  • 14. Behavioral differences in a rotenone-induced hemiparkinsonian rat model developed following intranigral or median forebrain bundle infusion.
    Sindhu KM, Saravanan KS, Mohanakumar KP.
    Brain Res; 2005 Jul 27; 1051(1-2):25-34. PubMed ID: 15992782
    [Abstract] [Full Text] [Related]

  • 15. Neuroprotective effect of the antiparkinsonian drug pramipexole against nigrostriatal dopaminergic degeneration in rotenone-treated mice.
    Inden M, Kitamura Y, Tamaki A, Yanagida T, Shibaike T, Yamamoto A, Takata K, Yasui H, Taira T, Ariga H, Taniguchi T.
    Neurochem Int; 2009 Dec 27; 55(8):760-7. PubMed ID: 19647776
    [Abstract] [Full Text] [Related]

  • 16. Physiological neuroprotection by melatonin in a 6-hydroxydopamine model of Parkinson's disease.
    Sharma R, McMillan CR, Tenn CC, Niles LP.
    Brain Res; 2006 Jan 12; 1068(1):230-6. PubMed ID: 16375867
    [Abstract] [Full Text] [Related]

  • 17. Selective A2A receptors blockade reduces degeneration of substantia nigra dopamine neurons in a rotenone-induced rat model of Parkinson's disease: A histological study.
    Fathalla AM, Soliman AM, Moustafa AA.
    Neurosci Lett; 2017 Mar 16; 643():89-96. PubMed ID: 28213070
    [Abstract] [Full Text] [Related]

  • 18. Rotenone induces oxidative stress and dopaminergic neuron damage in organotypic substantia nigra cultures.
    Testa CM, Sherer TB, Greenamyre JT.
    Brain Res Mol Brain Res; 2005 Mar 24; 134(1):109-18. PubMed ID: 15790535
    [Abstract] [Full Text] [Related]

  • 19. Dopamine D₁ and D₂ receptor subtypes functional regulation in corpus striatum of unilateral rotenone lesioned Parkinson's rat model: effect of serotonin, dopamine and norepinephrine.
    Paul J, Nandhu MS, Kuruvilla KP, Paulose CS.
    Neurol Res; 2010 Nov 24; 32(9):918-24. PubMed ID: 20887679
    [Abstract] [Full Text] [Related]

  • 20. Role of L-thyroxin in counteracting rotenone induced neurotoxicity in rats.
    Salama M, Helmy B, El-Gamal M, Reda A, Ellaithy A, Tantawy D, Mohamed M, El-Gamal A, Sheashaa H, Sobh M.
    Environ Toxicol Pharmacol; 2013 Mar 24; 35(2):270-7. PubMed ID: 23357603
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.